KCM
CAPR icon

Kennedy Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Kennedy Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-94,420
Closed -$681K – 544
2025
Q3 		$681K Buy
94,420
+19,401
+26% +$143K 0.02% 523
2025
Q2 		$745K Sell
75,019
-78,468
-51% -$829K 0.02% 527
2025
Q1 		$1.46M Buy
153,487
+9,237
+6% +$128K 0.03% 469
2024
Q4 		$1.99M Buy
+144,250
New +$2.53M 0.04% 520

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's CAPR Position: Q4 2025 in Review

Kennedy Capital Management sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 94,420 shares — an estimated $681K sold.

Kennedy Capital Management first reported a position in CAPR in Q4 2024 and held it in 4 quarters. The position peaked at $1.99M in Q4 2024. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • Kennedy Capital Management reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 94,420 Capricor Therapeutics shares in Q4 2025, an estimated $681K.
  • Kennedy Capital Management first reported a position in Capricor Therapeutics in Q4 2024 and held it in 4 quarters.
  • Kennedy Capital Management's Capricor Therapeutics position peaked at $1.99M in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on Kennedy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.